welcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Comparison of Efficacy and Adverse Effects Between Methimazole 15 Mg+Inorganic Iodine 38 Mg/Day and Methimazole 30 Mg/Day as Initial Therapy for Graves’ Disease Patients With Moderate to Severe Hyperthyroidism
source: Thyroid: Official Journal of the American Thyroid Association
year: 2015
authors: Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M
summary/abstract:Background:
Methimazole (MMI) is usually used at an initial dose of 30 mg/day for severe Graves’ disease (GD) hyperthyroidism, but adverse effects are more frequent at this dose than at MMI 15 mg/day.
Objectives:
We designed a regimen to address the lack of a primary therapeutic effect of the MMI 15 mg/day by combining it with inorganic iodine at 38.2 mg/day. Our aim was to compare the two regimens (MMI 15 mg+inorganic iodine at 38.2 mg/day (M15+I) vs. MMI 30 mg/day (M30)) in terms of therapeutic effect, adverse effects, and remission rate.
Design and Patients:
In a prospective study, 310 patients with untreated GD (serum free thyroxine (fT4) ≥5 ng/dL) were assigned to one of the two regimens. Potassium iodide was discontinued in the M15+I group as soon as the serum fT4 level was within the reference range (0.8-1.6 ng/dL).
Results:
Percentages of patients achieving an fT4 level within reference range in ≤30, ≤60, or 90 days on the study treatment regimens were 45.3%, 73.9%, and 82.0% respectively for the M15+I group, and 24.8%, 63.1%, and 75.2% respectively for the M30 group. Hence, the proportions of patients achieving this goal in ≤30 or ≤60 days were significantly larger in the M15+I group. Adverse effects that required discontinuation of MMI were more frequent in the M30-treated than in the M15+I-treated group (14.8% vs. 7.5%; p=0.0387). The remission rates in the M15+I and M30 groups were 19.9% and 14.8%-higher in the former, but the difference did not reach statistical significance.
Conclusion:
The results of this study raise the possibility that M15+I is superior to M30 as a primary treatment for moderate to severe hyperthyroidism caused by GD.
DOI: 10.1089/thy.2014.0084
rareRelated
-
University of Miami Health SystemWe leverage the latest research complete...
-
Graves’ DiseaseEpidemiology: Most common cause of Thyr...
-
National Institutes of Health Office of Dietary SupplementsThe Office of Dietary Supplements (ODS) ...
-
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
-
Vanderbilt University Medical Center – Thyroid CenterThyroid diseases can affect your overall...
-
Sara Tullis Wester, MD, FACSSara Tullis Wester is an Associate Profe...
-
The British Association of Endocrine and Thyroid SurgeonsThe British Association of Endocrine and...